Mirabegron and Dry eyes - a phase IV clinical study of FDA data

Summary:

Dry eyes is reported as a side effect among people who take Mirabegron (mirabegron), especially for people who are female, 60+ old, have been taking the drug for 1 - 6 months also take Glucosamine, and have Hypertonic bladder.

The phase IV clinical study analyzes which people have Dry eyes when taking Mirabegron. It is created by eHealthMe based on reports of 5,378 people who have side effects when taking Mirabegron from the FDA, and is updated regularly.

What is Mirabegron?

Mirabegron has active ingredients of mirabegron. It is often used in urge incontinence. eHealthMe is studying from 5,414 Mirabegron users. Check the latest studies of Mirabegron.

What is Dry eyes?

Dry eyes (lack of adequate tears) is found to be associated with 1,580 drugs and 2,053 conditions by eHealthMe. Check the latest studies of Dry eyes.

On Jul, 16, 2026

5,378 people reported to have side effects when taking Mirabegron.
Among them, 19 people (0.35%) have Dry eyes.

Among these 19 people:

How long have people been on Mirabegron when they have Dry eyes? *

What is the gender of people who have Dry eyes when taking Mirabegron? *

female: 69.23 %
male: 30.77 %

What is the age of people who have Dry eyes when taking Mirabegron? *

What are other drugs people take besides Mirabegron? *

What are other side effects people have besides Dry eyes? *

Dry Mouth: 10 people, 52.63%
Pain In Extremity: 8 people, 42.11%
Pain: 7 people, 36.84%
Itching: 6 people, 31.58%
Joint Pain: 6 people, 31.58%
Nasopharyngitis (inflammation of the nasopharynx): 6 people, 31.58%
Joint Effusion (presence of extra fluid in joint covering): 6 people, 31.58%
Cough: 5 people, 26.32%
Dizziness: 5 people, 26.32%
Fatigue (feeling of tiredness): 5 people, 26.32%

What are the existing conditions these people have? *

Hypertonic Bladder (bladder-storage function that causes a sudden urge to urinate): 5 people, 26.32%
Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 4 people, 21.05%
Gingivitis (inflammation of gums): 4 people, 21.05%
Relapsing-Remitting Multiple Sclerosis (reoccurrence of an inflammatory disease in which the insulating covers of nerve cells in the brain and spinal cord are damaged): 2 people, 10.53%
Primary Progressive Multiple Sclerosis (primary progressive inflammatory disease in which the insulating covers of nerve cells in the brain and spinal cord are damaged): 2 people, 10.53%
Pain: 2 people, 10.53%
Urination - Painful: 1 person, 5.26%
Prostatomegaly (enlargement of the prostate): 1 person, 5.26%
Prostatic Obstruction (urinary flow along the urinary tract is impaired by prostate enlargement): 1 person, 5.26%
Incontinence (lack of moderation or self-control): 1 person, 5.26%

* Approximation only. Some reports may have incomplete information.

Do you take Mirabegron and have Dry eyes?

- Check whether Dry eyes is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Mirabegron:

Mirabegron (5,414 reports)

Dry eyes treatments and more:

Dry eyes (76,573 reports)

Browse all side effects of Mirabegron:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Dry eyes:

Dry eyes (1,580 drugs)

Browse all the conditions that are associated with Dry eyes:

Dry eyes (2,053 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on mirabegron (the active ingredients of Mirabegron) and Mirabegron (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.